Wall Street brokerages expect Albireo Pharma Inc (NASDAQ:ALBO) to report ($0.97) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have issued estimates for Albireo Pharma’s earnings, with the lowest EPS estimate coming in at ($1.08) and the highest estimate coming in at ($0.68). Albireo Pharma reported earnings of ($0.73) per share during the same quarter last year, which indicates a negative year over year growth rate of 32.9%. The firm is expected to report its next earnings results on Tuesday, November 13th.

On average, analysts expect that Albireo Pharma will report full year earnings of ($3.39) per share for the current fiscal year, with EPS estimates ranging from ($3.70) to ($2.75). For the next year, analysts expect that the firm will post earnings of ($3.95) per share, with EPS estimates ranging from ($6.06) to ($2.13). Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for Albireo Pharma.

Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.24). The company had revenue of $0.73 million for the quarter, compared to analyst estimates of $2.00 million.

A number of analysts recently weighed in on the stock. BidaskClub lowered shares of Albireo Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, September 18th. Wedbush reaffirmed an “outperform” rating and set a $69.00 target price on shares of Albireo Pharma in a report on Tuesday, June 12th. Finally, Zacks Investment Research lowered shares of Albireo Pharma from a “buy” rating to a “hold” rating in a report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $59.40.

In other news, insider Ronald Harold Wilfred Cooper purchased 788 shares of Albireo Pharma stock in a transaction dated Tuesday, August 14th. The shares were bought at an average cost of $31.85 per share, with a total value of $25,097.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.60% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of ALBO. BlackRock Inc. increased its stake in Albireo Pharma by 582.8% in the 2nd quarter. BlackRock Inc. now owns 524,276 shares of the biopharmaceutical company’s stock valued at $18,611,000 after buying an additional 447,496 shares during the last quarter. Federated Investors Inc. PA acquired a new stake in Albireo Pharma in the 1st quarter valued at $10,094,000. Millennium Management LLC increased its stake in Albireo Pharma by 234.0% in the 1st quarter. Millennium Management LLC now owns 155,611 shares of the biopharmaceutical company’s stock valued at $5,068,000 after buying an additional 109,017 shares during the last quarter. Heartland Advisors Inc. acquired a new stake in Albireo Pharma in the 1st quarter valued at $2,974,000. Finally, Northern Trust Corp increased its stake in Albireo Pharma by 533.1% in the 2nd quarter. Northern Trust Corp now owns 99,819 shares of the biopharmaceutical company’s stock valued at $3,544,000 after buying an additional 84,053 shares during the last quarter. 63.41% of the stock is currently owned by institutional investors and hedge funds.

Shares of Albireo Pharma stock opened at $31.86 on Friday. The company has a market capitalization of $376.33 million, a P/E ratio of -10.11 and a beta of 1.28. Albireo Pharma has a fifty-two week low of $20.25 and a fifty-two week high of $39.87.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Read More: How Short Selling Works

Get a free copy of the Zacks research report on Albireo Pharma (ALBO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.